Stock data
Halozyme Therapeutics, Inc. (HALO)
Halozyme Therapeutics, Inc. (HALO) reported revenue of US$1.40B and net income of US$316.89M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$1.40B | — | US$469.01M | US$316.89M | — |
| 2024 | US$1.02B | — | US$551.48M | US$444.09M | — |
| 2023 | US$829.25M | — | US$337.57M | US$281.59M | — |
| 2022 | US$660.12M | — | US$267.53M | US$202.13M | — |
| 2021 | US$443.31M | — | US$275.90M | US$402.71M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$481.00M | US$229.91M | — |
| 2026-03-31 | US$376.71M | US$150.05M | — |
| 2025-12-31 | US$451.77M | -US$141.59M | — |
| 2025-09-30 | US$354.26M | US$175.22M | — |
| 2025-06-30 | US$325.72M | US$165.16M | — |
| 2025-03-31 | US$264.86M | US$118.09M | — |
| 2024-12-31 | US$298.01M | US$137.01M | — |
| 2024-09-30 | US$290.08M | US$137.01M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.